PragmaTIL: A randomized phase II study evaluating an IL-2 analogue (ANV419) versus high-dose IL-2 following tumor-infiltrating lymphocyte (TIL) therapy in advanced melanoma.

EJC Skin Cancer 2026 Open access

Read full text
Authors: M.J. Lostes Bardaji, V. Galvao, I. Mansfield Noringriis, R. Haunstrup Døssing, S. Klobuch, G. Pretelli, G. Villacampa, A. Lundqvist, S.L. Wickström, M. Donia, V. García-Patos Briones, C. Ferrándiz Pulido
+20 more E. Muñoz Couselo, M.A. Franzoi, P. Cacilhas, G. Jacob, F. Le Moal, S. Everhard, I. Creus, X. Villalobos, M. Monràs, M. Moreno, I. Lopez, N. García Pazos, R. Shapira, Israel Luis, R. Kiessling, S. Martin Lluesma, A. Gros, J. Haanen, I.M. Svane, E. Garralda Cabanas
DOI: 10.1016/j.ejcskn.2026.100881
Cited by: 1

Fields of Study & Subjects

Immunotherapy and Immune Responses Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
EJC Skin Cancer
Publisher
Elsevier BV
Volume
4
Pages
100881–100881
Publication date
1 January 2026
Language
EN